Cargando…

Combined immunotherapy for advanced prostate cancer: Empowering the T cell army

Detalles Bibliográficos
Autores principales:	Suleman, Sufyan, Wei, Gong-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Second Military Medical University 2017
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772898/ https://www.ncbi.nlm.nih.gov/pubmed/29387551 http://dx.doi.org/10.1016/j.ajur.2017.04.003

Ejemplares similares

Expanding luminal epitheliums as cells of origin for prostate cancer
por: Gu, Yuexi, et al.
Publicado: (2021)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Outsmarting SARS-CoV-2 by empowering a decoy ACE2
por: Sokolowska, Milena
Publicado: (2020)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Methionine restriction sensitizes cancer cells to immunotherapy
por: Lu, Weiqin, et al.
Publicado: (2023)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer
por: Qiu, Haibo
Publicado: (2020)

A ‘fit’ microbiota to potentiate cancer immunotherapy
por: Rescigno, Maria
Publicado: (2015)

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Measuring single‐cell protein secretion in immunology: Technologies, advances, and applications
por: Bucheli, Olivia T. M., et al.
Publicado: (2021)

From Tpex to Tex: a journey through CD8(+) T cell responses in cancer immunotherapy
por: Messmer, Julia M., et al.
Publicado: (2023)

Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
por: Ullrich, Evelyn, et al.
Publicado: (2022)

Transcriptional suppression of CD8(+) T cell exhaustion for improving T cell immunotherapy
por: Yang, Xue, et al.
Publicado: (2021)

An effective platform for cancer immunotherapy: pooled knockin targeting for genome engineering
por: Jin, Ke, et al.
Publicado: (2020)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
por: Almeida, Catarina R., et al.
Publicado: (2021)

Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy
por: Du, Songtao, et al.
Publicado: (2023)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

CD5: from antiquated T cell marker to immunotherapy’s new hope
por: Schwarz, Sandra, et al.
Publicado: (2023)

New strategy for cancer immunotherapy: using live engineered bacteria for metabolic modulation
por: Li, Tong, et al.
Publicado: (2021)

Doubling down with CAR-T cell cancer immunotherapy: a two-step recognition circuit enables discrimination between target antigen high and low cancer cells
por: Charo, Jehad, et al.
Publicado: (2021)

A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination
por: Rafi, Mohammad A., et al.
Publicado: (2015)

Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?
por: Safinia, Niloufar, et al.
Publicado: (2021)

Cytotoxic FCER1G(+) innate-like T cells: new potential for tumour immunotherapy
por: Morrish, Emma, et al.
Publicado: (2022)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?
por: Lughezzani, Giovanni, et al.
Publicado: (2015)

Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs
por: Zhang, Zhihui, et al.
Publicado: (2021)

Can cannibalizing cancer cells challenge classic cell death classification?
por: Walton, Emma Louise
Publicado: (2017)

Likely a matter of time for Amyloid-β immunotherapy
por: Cunha, Andreia
Publicado: (2021)

Cancer Environment Immunotherapy: targeting TGF-β finds its way towards tissue healing and vasculature remodeling
por: Jin, Ke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0rgur61qf3ga3bheq8dc34e6ti